Quratis Inc. (KOSDAQ:348080)
South Korea · Delayed Price · Currency is KRW 948.00
-27.00 (-2.77%)
At close: Apr 2, 2026
Quratis Revenue
In the year 2025, Quratis had annual revenue of 2.46B KRW with 557.29% growth. Quratis had revenue of 259.75M in the quarter ending December 31, 2025, with 216.08% growth.
Revenue
2.46B
Revenue Growth
+557.29%
P/S Ratio
40.73
Revenue / Employee
n/a
Employees
n/a
Market Cap
100.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.46B | 2.08B | 557.29% |
| Dec 31, 2024 | 373.80M | -656.26M | -63.71% |
| Dec 31, 2023 | 1.03B | -6.49B | -86.31% |
| Dec 31, 2022 | 7.52B | 5.94B | 373.65% |
| Dec 31, 2021 | 1.59B | 1.48B | 1,344.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CTCBIO | 123.77B |
| KoBioLabs | 69.29B |
| Cell Biotech | 53.13B |
| Choong Ang Vaccine Laboratory | 39.19B |
| CORESTEMCHEMON | 20.16B |
| BIO-FD&C | 19.18B |
| TegoScience | 5.94B |
| NovMetaPharma | 1.30B |